Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
No HPO annotations are available for this condition.
Age of onset: adulthood.
AIP familial isolated pituitary adenoma (AIP-FIPA) is characterized by an increased risk of pituitary neuroendocrine tumors (PitNETs), including growth hormone (GH)-secreting PitNETs (somatotropinomas), prolactin-secreting PitNETs (prolactinomas), GH and prolactin cosecreting PitNETs (somatomammotropinomas), and nonfunctioning PitNETs (NF-PitNETs). Rarely, thyroid-stimulating hormone (TSH)-secreting adenomas (thyrotropinomas) are observed. To date, more than 300 individuals with a germline pathogenic variant in AIP have been reported in research articles, and there are more than 60 entries from molecular diagnostic laboratories included in ClinVar . The following description of the phenotypic features associated with this condition is based on these reports.
AIP familial isolated pituitary adenoma (AIP-FIPA) should be suspected in probands with the following:
A pituitary neuroendocrine tumor (PitNET) diagnosed before age 18 years, especially a growth hormone (GH)-secreting PitNET, regardless of family history
A pituitary macroadenoma (tumor 10 mm in diameter) diagnosed before age 30 years, especially a GH-secreting PitNET, regardless of family history
No approved treatments are currently available for familial isolated pituitary adenoma. The disease remains an area of unmet medical need.
Recent clinical practice guidelines for pediatric pituitary neuroendocrine tumors (PitNETs), as well as acromegaly and prolactinoma, include management suggestions for hereditary pituitary tumors [, , , ]. Nevertheless, as no specific familial isolated pituitary adenoma (FIPA) guideline exists, the following recommendations also include the authors' personal experience managing individuals with this disorder.
No formal guidelines regarding surveillance of persons with AIP-FIPA have been established. The following recommendations are based on expert opinion from the literature and on the authors' personal experience with more than 400 persons with symptomatic or asymptomatic AIP-FIPA.
Table 7.
AIP Familial Isolated Pituitary Adenoma: Recommended Surveillance
System/Concern | Evaluation | Frequency
2 clinical trials registered, 2 recruiting. Interventions under study include other interventions. Research is primarily sponsored by academic and government institutions.
11 publications have been identified in PubMed for familial isolated pituitary adenoma. Research spans Review / Meta-Analysis (27%), Basic Science / Preclinical (27%), and Case Report / Case Series (18%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 3 | 27% |
Data assembled from 5 of 12 sources · Last updated Sep 20, 2026, 1:06 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Table 2.
Source: GeneReviews — "AIP Familial Isolated Pituitary Adenomas"
A prolactin-secreting pituitary macroadenoma (tumor 10 mm in diameter) diagnosed before age 30 years, regardless of family history. A single individual with clinically presenting childhood-onset microadenoma (tumor 10 mm) has been identified in this setting .
Source: GeneReviews — "AIP Familial Isolated Pituitary Adenomas"
In children more often than in adults, pituitary neuroendocrine tumors (PitNETs) may be a manifestation of a genetic condition. PitNETs of genetic origin can be divided into isolated and syndromic categories. Familial Isolated Pituitary Adenomas (FIPA) FIPA is defined as a hereditary condition associated with PitNETs and no other features of a syndrome known to be associated with these tumors. X-linked acrogigantism (X-LAG), a second genetically characterized type of FIPA, is caused by duplication of GPR101. X-LAG, a highly penetrant disorder with female preponderance, is associated with pituitary hyperplasia or PitNET resulting in infant-onset growth hormone (GH) excess usually associated with hyperprolactinemia. Most individuals with X-LAG have a de novo duplication which is typically mosaic in males. Female-to-male transmission has been observed. Proposed associations requiring further validation. A single study reported germline heterozygous CDH23 variants in one third of families with FIPA and 12% of individuals with sporadic PitNETs from a single cohort. Cosegregation with the phenotype was proven in one family, but the variants were not functionally tested, and the findings have not been replicated in other cohorts . More recently, germline missense PAM variants were detected in a family with gigantism with reduced penetrance and were found to be overrepresented in individuals with sporadic PitNETs from two different cohorts . Loss of function was demonstrated in vitro for multiple variants . Families with FIPA of known or unknown cause can have homogeneous PitNET phenotypes (i.e., pituitary tumors of the same type) or heterogeneous phenotypes (i.e., pituitary tumors of different types). Aspects of FIPA that tend to differ between families with or without germline AIP pathogenic variant include: age of onset, number of persons affected in the family, male-to-female ratio, and typical adenoma types. Tumor variables may also include: size, aggressiveness, and response to treatment . Table 3. Comparison of Findings in Persons with Isolated PitNETs by Family History and Presence/Absence of a Germline AIP Pathogenic Variant
Characteristics | Familial Isolated Pituitary Adenoma (FIPA) | Simplex Somatotropinoma1 |
|---|---|---|
AIP-FIPA | X-LAG | FIPA of unknown cause |
Clinical features | Typical age of onset (range)2 | Adolescence (age 4-24 yrs) |
Average number of affected family members3 | 3-4 | Usually simplex cases, but 3 families w/2-3 affected members have been described |
Male-to-female ratio4 | 1:1 to 2:1 | 1:3 |
Adenoma features | Somatotropinomas/somatomammotropinomas4 | 70%-80% |
Source: GeneReviews — "AIP Familial Isolated Pituitary Adenomas"
To establish the extent of disease and needs of an individual diagnosed with AIP-FIPA, the evaluations summarized (if not performed as part of the evaluation that led to the diagnosis) are recommended (for details, see ).
Table 5.
AIP Familial Isolated Pituitary Adenoma: Recommended Evaluations Following Initial Diagnosis
System/Concern | Evaluation | Comment
| • LH, FSH, testosterone/estradiol
Visual field eval
Consultation w/endocrinologist
| DXA scan in those w/hypogonadism
Pituitary MRI | Beginning at age 10 yrs, or younger if PitNET is suspected
Somatotropinoma
(GH secreting) | • Evaluate for signs/symptoms of GH excess (e.g., stature, change in facial appearance, change in shoe size, ring size, headache, excessive sweating, joint pains, carpal tunnel syndrome).
Spot serum GH, IGF-1
| • Review of serial photographs for acromegalic changes
Measurement of parental heights
OGTT in persons w/findings of acromegaly
ACTH reserve if needed
| • Evaluate for manifestations of prolactin excess (e.g., menstrual history, galactorrhea, ...
Source: GeneReviews — "AIP Familial Isolated Pituitary Adenomas"
The Genetics of Endocrine Tumours - Familial Isolated Pituitary Adenoma – FIPA study is actively recruiting individuals with FIPA or childhood-onset PitNET (NCT00461188). GH receptor antagonists block the action of endogenous GH, thereby controlling disease manifestations such as headaches, soft tissue enlargement, diabetes mellitus, hypertension, and high insulin-like growth factor 1 (IGF-1) levels. In two individuals with AIP-related PitNETs resistant to treatment with first-generation somatostatin receptor ligands (SRLs), pasireotide, a second-generation multiligand SRL with affinity to multiple somatostatin receptors, was shown to achieve long-term control of disease .
Source: GeneReviews — "AIP Familial Isolated Pituitary Adenomas"
2 trials found
| • Measure height weight; calculate height velocity.
Evaluate for signs/symptoms of PitNET evaluate pubertal development.
| Annually beginning at age 4 yrs until adulthood1
Evaluate for signs/symptoms of PitNET. | Annually until age 30 yrs every 5 yrs between ages 30 50 yrs; earlier if symptomatic
Serum IGF-1, prolactin, estradiol/testosterone, LH, FSH, TSH, free thyroxine | • Annually from age 4 to 30 yrs; to date, no secreting PitNETs have developed after age 30 in those w/normal findings at age 30 yrs.
Blood tests if symptomatic after age 30 yrs
Pituitary MRI | • Baseline at age 10 yrs unless indicated earlier due to clinical findings
Repeat MRI every 5 yrs until age 30 yrs (if clinical pituitary function tests remain normal)
If clinical or biochemical abnormality: MRI can be performed between ages 30 50 yrs
FSH = follicle-stimulating hormone; IGF-1 = insulin-like growth factor 1; LH = luteinizing hormone; PitNETs = pituitary neuroendocrine tumors; TSH = thyroid-stimulating hormone
Source: GeneReviews — "AIP Familial Isolated Pituitary Adenomas"
Estimated prevalence: Unknown (Unknown prevalence).
Laboratory research |
3 |
27% |
Patient case studies | 2 | 18% |
Disease patterns and progression | 2 | 18% |
New treatment approaches | 1 | 9% |
de Lapiscina IM (2026). [PMID: 41912295](https://pubmed.ncbi.nlm.nih.gov/41912295/). *Vitam Horm*. [Review / Meta-Analysis]
Marino Picciola V (2026). [PMID: 42008033](https://pubmed.ncbi.nlm.nih.gov/42008033/). *Pituitary*. [Gene Therapy / Novel Therapeutics]
Martinez de Lapiscina I (2026). [PMID: 42045809](https://pubmed.ncbi.nlm.nih.gov/42045809/). *Eur J Endocrinol*. [Epidemiology / Natural History]
Carranza-Zavala BR (2026). [PMID: 41417093](https://pubmed.ncbi.nlm.nih.gov/41417093/). *Endocrine-related cancer*. [Case Report / Case Series]
Kidwell RL (2026). [PMID: 41639477](https://pubmed.ncbi.nlm.nih.gov/41639477/). *Journal of neuro-oncology*. [Basic Science / Preclinical]
Loughrey PB (2025). [PMID: 40070360](https://pubmed.ncbi.nlm.nih.gov/40070360/). *European journal of endocrinology*. [Epidemiology / Natural History]
Hernández-Ramírez LC (2025). [PMID: 39908201](https://pubmed.ncbi.nlm.nih.gov/39908201/). *The Journal of clinical endocrinology and metabolism*. [Review / Meta-Analysis]
Piazzola C (2025). [PMID: 41364279](https://pubmed.ncbi.nlm.nih.gov/41364279/). *Pituitary*. [Case Report / Case Series]
Shen AL (2024). [PMID: 38590848](https://pubmed.ncbi.nlm.nih.gov/38590848/). *Heliyon*. [Basic Science / Preclinical]
Daly AF (2024). [PMID: 38696651](https://pubmed.ncbi.nlm.nih.gov/38696651/). *Endocrine reviews*. [Basic Science / Preclinical]
Macroadenomas in vast majority |
Usually macroadenomas; less frequently, pituitary hyperplasia or a combination of PitNET hyperplasia |